

Zolinza (vorinostat) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
PATIENT INSURANCE ID NUMBER:			
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:			
IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF			
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):			
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:			
PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH: FREQUENCY:	LENGTH OF QUANTITY: THERAPY/REFILLS:		
☐ NEW THERAPY ☐ RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page.





Zolinza (vorinostat) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🔲 NO
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
$\hfill \square$ Moderate to severe rheumatoid arthritis		
□ Other diagnosis:	ICD-10:	
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information:		
Is the prescriber a Rheumatologist? □ Yes □ No		
Is the patient on concurrent treatment with another TNF inhibitor? \Box Yes \Box No		
Has the patient tried and had an inadequate response to a three month trial of Enbrel? Yes No		
Has the patient tried and had an inadequate response to a three month trial of Humira? ☐ Yes ☐ No		
Has the patient had a trial with methotrexate or another oral non-biologic disease modifying anti-rheumatic agent (DMARD) such as Imuran, Ridaura, Arava, Plaquenil, or sulfasalazine? Yes No		
Does the patient have chronic liver disease such as chronic hepatitis, fatty liver, nonalcoholic steatohepatitis (NASH), or elevated liver enzymes)? ☐ Yes ☐ No		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?		
information is received.	re covered on all plans. This request may	<u> </u>
the Health Plan, insurer, Medical Group	n provided is true and accurate to the best o or its designees may perform a routine uracy of the information reported on thi	audit and request the medical
Prescriber Signature or Electronic I.D.	Verification:	Date:
you are not the intended recipient, you are here	ompanying this transmission contain confidential by notified that any disclosure, copying, distribut have received this information in error, please no	cion, or action taken in reliance on the contents

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.